Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
暂无分享,去创建一个
Deepak L. Bhatt | E. Topol | Jersey Chen | E. Mahoney | D. Cohen | J. Jackson | S. Gabriel | C. Shi | E. Dunn | J. Caro | D. Cohen
[1] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[2] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[3] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[4] J. Gore,et al. Trends in community mortality due to coronary heart disease. , 2006, American heart journal.
[5] Deepak L. Bhatt,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.
[6] S. Yusuf,et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.
[7] Roland Chen,et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2005, Journal of the American College of Cardiology.
[8] S. Yusuf,et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. , 2005, Journal of the American College of Cardiology.
[9] J. Caro,et al. Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure , 2005, Circulation.
[10] P. Heidenreich,et al. A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone , 2005, Annals of Internal Medicine.
[11] E. Peterson,et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. , 2005, Journal of the American College of Cardiology.
[12] J. Caro,et al. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] Deepak L. Bhatt,et al. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2004, American heart journal.
[14] D. Owens,et al. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis ☆ , 2004 .
[15] J. D. de Lemos,et al. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. , 2003, The New England journal of medicine.
[16] S. Ramsey. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. , 2003, The New England journal of medicine.
[17] B J O'Brien,et al. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.
[18] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[19] C. Cannon,et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. , 2002, JAMA.
[20] Karen M Kuntz,et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. , 2002, The New England journal of medicine.
[21] P. Beck,et al. Health Databases in Saskatchewan , 2002 .
[22] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[23] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[24] A A Tsiatis,et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.
[25] M. Johannesson,et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.
[26] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[27] L. Goldman,et al. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. , 1996, Circulation.
[28] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[29] M A Koopmanschap,et al. The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.